MaxCyte Appoints Amanda L. Murphy as Chief Financial Officer and Names Ron Holtz as Senior Vice President & Chief Accounting Officer

Published on :

MaxCyte, Inc., a global cell-based therapies and life sciences company, announced today that Amanda L. Murphy, CFA, has joined the Company as Chief Financial Officer (CFO). Ron Holtz, who has served as MaxCyte’s CFO since 2005, will become Senior Vice President and Chief Accounting Officer (SVP & CAO).

Martha Sklavos, PhD, PMP Joins Arcellx as new Senior Director, Program Management

Published on :

Dr. Sklavos joins Arcellx with over 15 years of experience in biomedical and clinical research in academic, government and industry settings. Dr. Sklavos brings broad drug development expertise to Arcellx as a result of managing multiple complex projects and portfolios comprised of various drug modalities including monoclonal and bispecific antibodies, antibody drug conjugates, peptide conjugates, and cell therapies.

Novovax announced that Silvia Taylor, MBA, has joined the company as SVP, Investor Relations, and Corporate Affairs

Published on :

Novovax announced that Silvia Taylor, MBA, has joined the company as SVP, Investor Relations, and Corporate Affairs GAITHERSBURG, Md., June 17, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing [….]

Emergent BioSolutions Appoints Nina DeLorenzo as Senior Vice President of Global Public Affairs

Published on :

Emergent BioSolutions Appoints Nina DeLorenzo as Senior Vice President of Global Public Affairs GAITHERSBURG, Md., April 06, 2020 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of Nina DeLorenzo to the position [….]